- New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
- Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study
- [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity
- Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes
- Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)
- FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss
- [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer
- Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)
- CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition
- Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection
More ▼
Key statistics
On Monday, Roche Holding AG (RHO6:DUS) closed at 35.90, -0.28% below its 52-week high of 36.00, set on Jul 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 35.40 |
---|---|
High | 35.90 |
Low | 35.40 |
Bid | 35.90 |
Offer | 36.40 |
Previous close | 35.90 |
Average volume | 702.00 |
---|---|
Shares outstanding | 6.47bn |
Free float | 328.26m |
P/E (TTM) | 19.27 |
Market cap | 251.71bn USD |
EPS (TTM) | 2.02 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 18:32 BST.
More ▼